Capital Impact Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Capital Impact Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-189,437	Closed	-$1.39M	–	126
2019 Q1	$1.39M	Hold	189,437	–	–	0.61%	94
2018 Q4	$1.39M	Buy	189,437 +96,548	+104%	+$995K	0.59%	97
2018 Q3	$1.39M	Buy	92,889 +4,473	+5%	+$76.7K	0.48%	110
2018 Q2	$1.69M	Buy	88,416 +19,309	+28%	+$357K	0.63%	93
2018 Q1	$1.21M	Buy	69,107 +21,981	+47%	+$466K	0.5%	111
2017 Q4	$1.16M	Hold	47,126	–	–	0.5%	111
2017 Q3	$1.22M	Buy	47,126 +22,140	+89%	+$593K	0.54%	109
2017 Q2	$678K	Sell	24,986 -9,572	-28%	-$260K	0.31%	145
2017 Q1	$1.03M	Buy	+34,558	New	+$996K	0.41%	129

Other funds holding ACRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Capital Impact Advisors's ACRS Position: Q2 2019 in Review

Capital Impact Advisors sold out of Aclaris Therapeutics (ACRS) in Q2 2019, closing a stake of 189,437 shares — an estimated $1.39M sold.

Capital Impact Advisors first reported a position in ACRS in Q1 2017 and held it in 9 quarters. The position peaked at $1.69M in Q2 2018. 84 funds tracked by Wall St. Rank hold ACRS as of Q2 2019.

Capital Impact Advisors reported no remaining Aclaris Therapeutics position as of Q2 2019 after selling out during the quarter.
Capital Impact Advisors sold 189,437 Aclaris Therapeutics shares in Q2 2019, an estimated $1.39M.
Capital Impact Advisors first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 9 quarters.
Capital Impact Advisors's Aclaris Therapeutics position peaked at $1.69M in Q2 2018.
84 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2019.

Based on Capital Impact Advisors's 13F filing for Q2 2019, filed 19 Jul 2019.